[go: up one dir, main page]

CO2019011299A2 - Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4 - Google Patents

Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4

Info

Publication number
CO2019011299A2
CO2019011299A2 CONC2019/0011299A CO2019011299A CO2019011299A2 CO 2019011299 A2 CO2019011299 A2 CO 2019011299A2 CO 2019011299 A CO2019011299 A CO 2019011299A CO 2019011299 A2 CO2019011299 A2 CO 2019011299A2
Authority
CO
Colombia
Prior art keywords
dialkoxystyryl
benzylsulfones
bioavailability
formulations
administration
Prior art date
Application number
CONC2019/0011299A
Other languages
English (en)
Inventor
Manoj Maniar
Original Assignee
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59856606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019011299(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onconova Therapeutics Inc filed Critical Onconova Therapeutics Inc
Publication of CO2019011299A2 publication Critical patent/CO2019011299A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen composiciones farmacéuticas de (E)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona y sales farmacéuticamente aceptables de la misma, así como métodos de su uso.
CONC2019/0011299A 2017-04-13 2019-11-12 Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4 CO2019011299A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485355P 2017-04-13 2017-04-13
PCT/US2018/027514 WO2018191634A2 (en) 2017-04-13 2018-04-13 Formulations with enhanced stability and bioavailability for administration of (e)-2,6- dialkoxystyryl 4-substituted benzylsulfones

Publications (1)

Publication Number Publication Date
CO2019011299A2 true CO2019011299A2 (es) 2020-02-18

Family

ID=59856606

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0011299A CO2019011299A2 (es) 2017-04-13 2019-11-12 Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4

Country Status (19)

Country Link
US (1) US10098862B1 (es)
EP (3) EP3609471B1 (es)
JP (1) JP7202313B2 (es)
KR (1) KR102643626B1 (es)
CN (2) CN110536678A (es)
AR (1) AR109503A1 (es)
AU (2) AU2018253291B2 (es)
BR (1) BR112019021445A2 (es)
CA (1) CA3058664A1 (es)
CL (1) CL2019002899A1 (es)
CO (1) CO2019011299A2 (es)
EA (1) EA201992436A1 (es)
ES (3) ES2941538T3 (es)
IL (2) IL269757B (es)
MX (1) MX2022011860A (es)
TW (2) TWI809721B (es)
UY (1) UY37380A (es)
WO (2) WO2018190897A1 (es)
ZA (2) ZA201906671B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382877B2 (en) 2017-04-13 2022-07-12 Onconova Therapeutics, Inc. Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US12156856B2 (en) 2017-04-13 2024-12-03 Traws Pharma, Inc. Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4588323B2 (ja) 2002-02-28 2010-12-01 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 増殖性疾患を治療するためのアミノ置換（ｅ）−２，６−ジアルコキシスチリル−４−置換ベンジルスルホン
ATE497768T1 (de) 2004-07-19 2011-02-15 Onconova Therapeutics Inc Formulierungen für die parenterale verabreichung von (e)-2,6-dialkoxystryryl 4-substituierten benzylsulfonen
WO2008027049A1 (en) 2006-08-30 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
JP2010515772A (ja) 2007-01-16 2010-05-13 オンコノバ・セラピューティックス・インコーポレーテッド （ｅ）−２，６−ジアルコキシスチリル４−置換ベンジルスルホン類の非経口投与用製剤
CA2864118A1 (en) 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
JP6462582B2 (ja) 2012-12-07 2019-01-30 オンコノバ・セラピューティックス・インコーポレーテッド がんの治療のための方法および組成物

Also Published As

Publication number Publication date
IL269757A (en) 2019-11-28
US10098862B1 (en) 2018-10-16
IL289806B1 (en) 2024-02-01
AR109503A1 (es) 2018-12-19
AU2018253291B2 (en) 2024-05-02
WO2018191634A3 (en) 2019-04-11
EP3733163B1 (en) 2022-06-08
ES2941538T3 (es) 2023-05-23
ZA202107580B (en) 2023-11-29
IL289806A (en) 2022-03-01
CL2019002899A1 (es) 2020-02-28
KR102643626B1 (ko) 2024-03-06
TWI809721B (zh) 2023-07-21
MX2022011860A (es) 2022-10-20
AU2018253291A1 (en) 2019-10-24
ES2993599T3 (en) 2025-01-02
IL289806B2 (en) 2024-06-01
IL269757B (en) 2022-08-01
TW201836597A (zh) 2018-10-16
EP3733163A1 (en) 2020-11-04
WO2018191634A2 (en) 2018-10-18
CA3058664A1 (en) 2018-10-18
WO2018190897A1 (en) 2018-10-18
UY37380A (es) 2018-10-31
TWI759459B (zh) 2022-04-01
EA201992436A1 (ru) 2020-03-30
EP3609471B1 (en) 2023-01-04
TW202222303A (zh) 2022-06-16
CN110536678A (zh) 2019-12-03
AU2024205164A1 (en) 2024-08-15
EP4193988B1 (en) 2024-06-05
EP4193988A1 (en) 2023-06-14
ES2926042T3 (es) 2022-10-21
EP3733163B8 (en) 2022-09-28
JP2020516665A (ja) 2020-06-11
KR20190134705A (ko) 2019-12-04
JP7202313B2 (ja) 2023-01-11
CN116637095A (zh) 2023-08-25
WO2018191634A4 (en) 2019-06-20
US20180296513A1 (en) 2018-10-18
ZA201906671B (en) 2022-03-30
BR112019021445A2 (pt) 2020-05-05
EP3609471A2 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
IL284913A (en) Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
MX2020007148A (es) Formulaciones.
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
BR112015018087A8 (pt) composto, composição farmacêutica e uso
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
MX2019008435A (es) Inhibidores selectivos de jak1.
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
ECSP21030482A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
CY1122755T1 (el) Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO2020007044A2 (es) Derivados de pirrol como inhibidores de acc
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CU20210077A7 (es) Extractos bacterianos estables como fármacos
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
MX387785B (es) Compuestos heteroarilo y su uso como farmacos terapeuticos.
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
CO2019011299A2 (es) Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4
MX2025011781A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.